Assessment of live plague vaccine candidates

Valentina A. Feodorova, Lidiya V. Sayapina, Vladimir Motin

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Since its creation in the early twentieth century, live plague vaccine EV has been successfully applied to millions of people without severe complications. This vaccine has been proven to elicit protection against both bubonic and pneumonic plague, and it is still in use in populations at risk mainly in the countries of the former Soviet Union. Despite extensive efforts in developing subunit vaccines, there is a reviving interest in creation of a precisely attenuated strain of Yersinia pestis superior to the EV that can serve as a live plague vaccine with improved characteristics. Here we summarize decades of experience of the Russian anti-plague research in developing a standard protocol for early-stage evaluation of safety and immunogenicity of live plague vaccines. This protocol allows step-by-step comparison of the novel test candidates with the EV vaccine by using subcutaneous immunization and bubonic plague infection models in two animal species, e.g., guinea pigs and mice.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages487-498
Number of pages12
Volume1403
DOIs
StatePublished - Apr 1 2016

Publication series

NameMethods in Molecular Biology
Volume1403
ISSN (Print)10643745

Fingerprint

Plague Vaccine
Plague
Vaccines
Yersinia pestis
Subunit Vaccines
USSR
Immunization
Guinea Pigs
Safety
Infection
Research

Keywords

  • Animal model
  • Attenuation
  • Infectious disease
  • Live vaccine
  • Mutant
  • Plague
  • Protection
  • Vaccine candidate
  • Virulence
  • Yersinia pestis

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Feodorova, V. A., Sayapina, L. V., & Motin, V. (2016). Assessment of live plague vaccine candidates. In Methods in Molecular Biology (Vol. 1403, pp. 487-498). (Methods in Molecular Biology; Vol. 1403). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3387-7_27

Assessment of live plague vaccine candidates. / Feodorova, Valentina A.; Sayapina, Lidiya V.; Motin, Vladimir.

Methods in Molecular Biology. Vol. 1403 Humana Press Inc., 2016. p. 487-498 (Methods in Molecular Biology; Vol. 1403).

Research output: Chapter in Book/Report/Conference proceedingChapter

Feodorova, VA, Sayapina, LV & Motin, V 2016, Assessment of live plague vaccine candidates. in Methods in Molecular Biology. vol. 1403, Methods in Molecular Biology, vol. 1403, Humana Press Inc., pp. 487-498. https://doi.org/10.1007/978-1-4939-3387-7_27
Feodorova VA, Sayapina LV, Motin V. Assessment of live plague vaccine candidates. In Methods in Molecular Biology. Vol. 1403. Humana Press Inc. 2016. p. 487-498. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3387-7_27
Feodorova, Valentina A. ; Sayapina, Lidiya V. ; Motin, Vladimir. / Assessment of live plague vaccine candidates. Methods in Molecular Biology. Vol. 1403 Humana Press Inc., 2016. pp. 487-498 (Methods in Molecular Biology).
@inbook{d7117b25b82847bd8f4d0709ccd0f841,
title = "Assessment of live plague vaccine candidates",
abstract = "Since its creation in the early twentieth century, live plague vaccine EV has been successfully applied to millions of people without severe complications. This vaccine has been proven to elicit protection against both bubonic and pneumonic plague, and it is still in use in populations at risk mainly in the countries of the former Soviet Union. Despite extensive efforts in developing subunit vaccines, there is a reviving interest in creation of a precisely attenuated strain of Yersinia pestis superior to the EV that can serve as a live plague vaccine with improved characteristics. Here we summarize decades of experience of the Russian anti-plague research in developing a standard protocol for early-stage evaluation of safety and immunogenicity of live plague vaccines. This protocol allows step-by-step comparison of the novel test candidates with the EV vaccine by using subcutaneous immunization and bubonic plague infection models in two animal species, e.g., guinea pigs and mice.",
keywords = "Animal model, Attenuation, Infectious disease, Live vaccine, Mutant, Plague, Protection, Vaccine candidate, Virulence, Yersinia pestis",
author = "Feodorova, {Valentina A.} and Sayapina, {Lidiya V.} and Vladimir Motin",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/978-1-4939-3387-7_27",
language = "English (US)",
volume = "1403",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "487--498",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Assessment of live plague vaccine candidates

AU - Feodorova, Valentina A.

AU - Sayapina, Lidiya V.

AU - Motin, Vladimir

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Since its creation in the early twentieth century, live plague vaccine EV has been successfully applied to millions of people without severe complications. This vaccine has been proven to elicit protection against both bubonic and pneumonic plague, and it is still in use in populations at risk mainly in the countries of the former Soviet Union. Despite extensive efforts in developing subunit vaccines, there is a reviving interest in creation of a precisely attenuated strain of Yersinia pestis superior to the EV that can serve as a live plague vaccine with improved characteristics. Here we summarize decades of experience of the Russian anti-plague research in developing a standard protocol for early-stage evaluation of safety and immunogenicity of live plague vaccines. This protocol allows step-by-step comparison of the novel test candidates with the EV vaccine by using subcutaneous immunization and bubonic plague infection models in two animal species, e.g., guinea pigs and mice.

AB - Since its creation in the early twentieth century, live plague vaccine EV has been successfully applied to millions of people without severe complications. This vaccine has been proven to elicit protection against both bubonic and pneumonic plague, and it is still in use in populations at risk mainly in the countries of the former Soviet Union. Despite extensive efforts in developing subunit vaccines, there is a reviving interest in creation of a precisely attenuated strain of Yersinia pestis superior to the EV that can serve as a live plague vaccine with improved characteristics. Here we summarize decades of experience of the Russian anti-plague research in developing a standard protocol for early-stage evaluation of safety and immunogenicity of live plague vaccines. This protocol allows step-by-step comparison of the novel test candidates with the EV vaccine by using subcutaneous immunization and bubonic plague infection models in two animal species, e.g., guinea pigs and mice.

KW - Animal model

KW - Attenuation

KW - Infectious disease

KW - Live vaccine

KW - Mutant

KW - Plague

KW - Protection

KW - Vaccine candidate

KW - Virulence

KW - Yersinia pestis

UR - http://www.scopus.com/inward/record.url?scp=84963801039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963801039&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3387-7_27

DO - 10.1007/978-1-4939-3387-7_27

M3 - Chapter

VL - 1403

T3 - Methods in Molecular Biology

SP - 487

EP - 498

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -